Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 20/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22938646 | 1.00 | ABL1 (0.56) | ABL1OPRM1KCNH2 | |
| SCHEMBL28523803 | 0.90 | ABL1 (0.54) | ABL1 | |
| SCHEMBL22939415 | 0.85 | ABL1 (0.53) | ABL1 | |
| SCHEMBL30046925 | 0.85 | ABL1 (0.53) | ABL1 | |
| SCHEMBL22938707 | 0.84 | ABL1 (0.64) | ABL1KCNH2 | |
| SCHEMBL30046879 | 0.84 | ABL1 (0.64) | ABL1KCNH2 | |
| SCHEMBL22939418 | 0.83 | ABL1 (0.48) | ABL1 | |
| SCHEMBL30046805 | 0.83 | ABL1 (0.48) | ABL1 | |
| SCHEMBL23091734 | 0.82 | ABL1 (0.62) | ABL1OPRM1KCNH2 | |
| SCHEMBL29687314 | 0.82 | ABL1 (0.62) | ABL1OPRM1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220332701-A1 | HETEROCYCLIC COMPOUNDS AS BCR-ABL INHIBITORS | ASCENTAGE PHARMA GROUP CORP LIMITED (HK) | 2022-10-20 | — | — | US | claimed |
| US-20220332701-A1 | HETEROCYCLIC COMPOUNDS AS BCR-ABL INHIBITORS | ASCENTAGE PHARMA GROUP CORP LIMITED (HK) | 2022-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332701-A1 | HETEROCYCLIC COMPOUNDS AS BCR-ABL INHIBITORS | ABL1, ABL2, BCR | ABL1 1/4885OPRM1 2701/4885KCNH2 2583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.